Non Hodgkin's Lymphoma

Match Related Donor
- Not Eligible for Full Dose Conditioning
  - BMT238: Phase II Allogeneic CD8 Memory T-Cells Infusion as Consolidative Tx After HCT in Leukemia & Lymphoma
    PI: Lowsky
    Stanford
  - BMT236: Phase II/III MAHCT w/T Cell Depleted Graft w/Infusion of Conventional and Regulatory T Cells
    PI: Meyer
    NIH
- High Dose Chemotherapy Required
  - BMT206: Phase II Non-myeloablative Allogeneic Transplant Using TLI & ATG In Cutaneous T Cell Lymphoma
    PI: Weng
    Stanford

Unrelated Donor
- Mycosis Fungoides/Sezary Syndrome
  - BMT206: Phase II Non-myeloablative Allogeneic Transplant Using TLI & ATG In Cutaneous T Cell Lymphoma
    PI: Weng
    Stanford

Mantle Cell Lymphoma
- Ibrutinib Resistance
  - BMT310: Phase II KTE-C19 in Relapsed/Refractory Mantle Cell Lymphoma
    PI: Miklos
    Kite Pharma
- Histocompatible donor
  - BMT316: Phase II Optimizing Post-Allogeneic HCT Outcomes In Lymphoma Using Ibrutinib
    PI: Miklos
    Vanderbilt University

BMT330: Phase II Very Low Dose Total Body Irradiation in Combination with Total Lymphoid Irradiation and anti-Thymocyte Globulin to Improve Donor Engraftment in Patients Undergoing Non-MHCT
PI: Muffy
Sponsor: Stanford